MedPath

安徽智飞龙科马生物制药有限公司

Ownership
-
Established
2001-01-05
Employees
-
Market Cap
-
Website
www.zhifeishengwu.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

8

NMPA:8

Drug Approvals

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Product Name
四价流感病毒裂解疫苗
Approval Number
国药准字S20250015
Approval Date
Mar 18, 2025
NMPA

Recombinant Mycobacterium Tuberculosis Fusion Protein(EC)

Product Name
宜卡
Approval Number
国药准字S20237004
Approval Date
Mar 13, 2023
NMPA

Recombinant COVID-19 Vaccine(CHO Cell)

Product Name
智克威得
Approval Number
国药准字S20220009
Approval Date
Feb 28, 2023
NMPA

Recombinant COVID-19 Vaccine(CHO Cell)

Product Name
智克威得
Approval Number
国药准字S20220010
Approval Date
Feb 28, 2023
NMPA

Mycobacterium vaccae for Injection

Product Name
微卡
Approval Number
国药准字S20010003
Approval Date
Jul 3, 2020
NMPA

Recombinant Mycobacterium Tuberculosis Fusion Protein(EC)

Product Name
宜卡
Approval Number
国药准字S20200006
Approval Date
Apr 23, 2020
NMPA

Recombinant Mycobacterium Tuberculosis Fusion Protein(EC)

Product Name
宜卡
Approval Number
国药准字S20200004
Approval Date
Apr 23, 2020
NMPA

Recombinant Mycobacterium Tuberculosis Fusion Protein(EC)

Product Name
宜卡
Approval Number
国药准字S20200005
Approval Date
Apr 23, 2020
NMPA

Clinical Trials

No trials found

News

No news found
© Copyright 2025. All Rights Reserved by MedPath